← Back to Search

Diagnostic Imaging Techniques for Shoulder Osteoarthritis (UESOA Trial)

N/A
Waitlist Available
Led By Peter Lapner, MD, FRCSC
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults <60 years of age
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5-years post-allocation
Awards & highlights

UESOA Trial Summary

This trial is investigating the development of shoulder OA.

Who is the study for?
This trial is for adults under 60 with shoulder osteoarthritis, specifically those showing more than 55% posterior humeral head subluxation on imaging. It's not suitable for individuals over 60, those with labral or rotator cuff issues, pre-existing joint deformities beyond grade I, neurological disorders of the upper limb, history of shoulder instability or trauma including fractures.Check my eligibility
What is being tested?
The study aims to understand the causes and progression of shoulder osteoarthritis by using low-dose CT scans, T1Rho MRI imaging techniques and motion analysis to observe changes in the joint over time.See study design
What are the potential side effects?
While this study involves diagnostic tests rather than treatments, potential side effects may include discomfort during motion analysis and exposure to radiation from CT scans. The MRI procedure is generally safe but may cause claustrophobia or discomfort.

UESOA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am younger than 60 years old.

UESOA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5-years post-allocation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5-years post-allocation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Finite Element Analysis
Motion Analysis
Magnetic Resonance Imaging
+1 more

UESOA Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group 1: Early Degeneration ('Disease')Experimental Treatment3 Interventions
Those who have posterior subluxation of the humeral head and show early signs of degeneration in their shoulder.
Group II: Group 2: No Degeneration ('Healthy')Active Control3 Interventions
Those who have posterior subluxation of the humeral head and show no signs of degeneration.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Low-dose CT
2015
N/A
~60

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
563 Previous Clinical Trials
2,787,657 Total Patients Enrolled
University of OttawaOTHER
210 Previous Clinical Trials
268,132 Total Patients Enrolled
Peter Lapner, MD, FRCSCPrincipal InvestigatorThe Ottawa Hospital Research Institute

Media Library

Motion Analysis Clinical Trial Eligibility Overview. Trial Name: NCT04634773 — N/A
Shoulder Osteoarthritis Research Study Groups: Group 1: Early Degeneration ('Disease'), Group 2: No Degeneration ('Healthy')
Shoulder Osteoarthritis Clinical Trial 2023: Motion Analysis Highlights & Side Effects. Trial Name: NCT04634773 — N/A
Motion Analysis 2023 Treatment Timeline for Medical Study. Trial Name: NCT04634773 — N/A
~27 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top